Key Findings
The global auto injectors market is growing with the CAGR of 19.2% and the revenue is estimated to grow around $3550 million during the forecast period of 2016-2022. An auto injector is a medical device manufactured to deliver a dose of a specific drug. An auto injector commonly consists of a pre-filled syringe (or cartridge) within a device which makes easier the supply of the desired biologic under important specifications. The auto injector in recent years has become a famous option for biopharmaceutical companies as a drug delivery device owing to its robustness in accommodating injection requirements, the integrated safety, and convenience characteristics that enable patients to more comfortably administer injections by own.
The key factor that helps driving the market is the adoption of advanced drug delivery systems & techniques. Manufacturing and synthesis of effective drug delivery devices are of high importance for healthcare and medicine. Nanotechnology and materials innovation have synergistically enhanced the advancement of drug delivery. Advancements in material chemistry enables the generation of biocompatible, environment-responsive, biodegradable and focused drug delivery systems. Nanotechnology allows control over shape, size and multi-functionality of particular drug delivery system. The key companies focus on the processing of drug delivery systems and materials innovation and are continuously trying to expand the future of advanced drug delivery. Auto injector is an advanced drug delivery device that has great importance in the new medical science.
The major driving factors for the auto-injectors market are the rising prevalence of chronic diseases across the globe, rising awareness of auto injectors regarding use and efficacy, and growing prevalence of rheumatoid arthritis in developing economies. Apart from this, there is a rise in the research & development activities in the field of auto injectors that also act as a driving force for the market.
The market is facing a restraint i.e. side effects of epinephrine auto injectors. The industry has huge opportunities such as favorable reimbursement policies and increasing prevalence of anaphylaxis in developed nations. The major market challenge is the high prices of auto injectors.
Market Segment Insight
Auto injectors market is segmented on the basis of therapeutic application, types and geography. On the basis of therapeutic application, the market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis and others. According to application, the anaphylaxis segment is the dominating and rapid growing market primarily owing to increasing awareness regarding epinephrine auto-injectors, raising prevalence of the disease and benefits of its use for anaphylaxis management under emergency conditions.
On the basis of type, the market is segmented into fillable auto injectors, prefilled auto injectors and others. Prefilled auto-injectors are leading the auto-injectors market due to its special feature i.e. simple to use. Rising patient awareness regarding these auto injectors is also boosting the demand for prefilled auto injectors.
Regional Insight
On the basis of geography, the market is segmented into North America, Europe, Asia Pacific and RoW. North America was the leader in the global auto-injectors market in 2013 due to economic stability to purchase expensive auto-injectors, favorable government reimbursement policies and rising prevalence of anaphylaxis in the region. However, Asia Pacific is expected to be the fastest growing region for auto-injectors market during the forecast period due to increasing prevalence of multiple sclerosis and anaphylaxis in Australia and New Zealand and rising government reimbursement options in New Zealand, and increasing awareness about novel treatment procedures present in the market.
Competitive Insights
Some of the major players in the global auto injectors market are, Amedra Pharmaceuticals LLC, Antares Pharma, Inc., Becton-Dickinson and Company, Biogen Idec, Inc., Epipens, Mylan, Inc. Novartis International AG, Owen Mumford and PA Consulting Group Pfizer, Inc., Rebiject, SanofiSHL Group, Unilife Corporation, Ypsomed Holdings AG. These key companies have adopted major strategies such as mergers, acquisitions; agreement, new product launch etc to expand their market share globally. One of the major strategy adopted by the key player Novartis International AG is on Oct 2014, the Novartis launched a new product ExtaviPro® 30G for Multiple Sclerosis. Novartis Pharmaceuticals Ltd has introduced ExtaviPro® 30G, an upgraded autoinjector device for the management of the medicine Extavia® (interferon beta 1b), which is used for the treatment for Multiple Sclerosis. The ExtaviPro 30G device supplies exactly the similar dose of the medicine interferon beta 1b like the previous ExtaviJect® autoinjector. The new thing in the product is that it is the delivery device itself. The auto injector delivery device has been advanced to offer a rounded tip produced for a high comfortable fit against the skin and light, ergonomic design that enables easy access and one-handed utilization to all recommended injection sites. Contained inside the advanced new auto injector is an ultrathin 30 gauge recessed needle and the syringe is hidden under the delivery device.
CHAP 1. METHODOLOGY & SCOPE 12
1.1. RESEARCH METHODOLOGY 12
1.2. RESEARCH SCOPE & ASSUMPTIONS 12
1.3. LIST OF DATA SOURCES 12
CHAP 2. EXECUTIVE SUMMARY 13
2.1. GLOBAL AUTO INJECTORS MARKET SUMMARY & KEY BUYING CRITERIA 13
2.2. GLOBAL AUTO INJECTORS MARKET OUTLOOK 13
2.3. MARKET SEGMENTATION ANALYSIS 13
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 13
2.5. GLOBAL AUTO INJECTORS MARKET VALUE CHAIN ANALYSIS 13
2.6. VENDOR LANDSCAPE 13
CHAP 3. GLOBAL AUTO INJECTORS MARKET 14
3.1. MARKET DRIVER ANALYSIS 14
3.1.1. RISING PREVALENCE OF CHRONIC DISEASES ACROSS THE GLOBE. 14
3.1.2. ADOPTION OF ADVANCED DRUG DELIVERY SYSTEMS & TECHNIQUES. 14
3.1.3. RISING AWARENESS OF AUTO INJECTORS REGARDING USE AND EFFICACY. 14
3.1.4. INCREASING PREVALENCE OF RHEUMATOID ARTHRITIS IN DEVELOPING ECONOMIES 14
3.2. MARKET RESTRAINT ANALYSIS 14
3.2.1. SIDE-EFFECTS OF EPINEPHRINE AUTO-INJECTORS. 14
3.3. KEY OPPORTUNITIES 14
3.3.1. FAVORABLE REIMBURSEMENT POLICIES 14
3.3.2. INCREASING PREVALENCE OF ANAPHYLAXIS IN DEVELOPED NATIONS. 14
3.4. CHALLENGES 14
3.4.1. HIGH PRICES OF AUTO INJECTORS 14
CHAP 4. INDUSTRY ANALYSIS 15
4.1. GLOBAL AUTO INJECTORS MARKET– PORTER’S FIVE FORCE MODEL 15
4.2. GLOBAL AUTO INJECTORS MARKET– PESTEL ANALYSIS 15
4.3. GLOBAL AUTO INJECTORS MARKET– GAP ANALYSIS 15
CHAP 5. GLOBAL AUTO INJECTORS MARKET BY THERAPEUTIC APPLICATION 2012-2022 ($ MILLION) 16
5.1. GLOBAL AUTO INJECTORS MARKET BY RHEUMATOID ARTHRITIS 2012-2022 ($ MILLION) 16
5.2. GLOBAL AUTO INJECTORS MARKET BY MULTIPLE SCLEROSIS 2012-2022 ($ MILLION) 16
5.3. GLOBAL AUTO INJECTORS MARKET BY ANAPHYLAXIS 2012-2022 ($ MILLION) 16
5.4. GLOBAL AUTO INJECTORS MARKET BY OTHERS 2012-2022 ($ MILLION) 16
CHAP 6. GLOBAL AUTO INJECTORS MARKET BY TYPES 2012-2022 ($ MILLION) 17
6.1. GLOBAL AUTO INJECTORS MARKET BY FILLABLE AUTO-INJECTORS 2012-2022 ($ MILLION) 17
6.2. GLOBAL AUTO INJECTORS MARKET BY PREFILLED AUTO-INJECTORS 2012-2022 ($ MILLION) 17
6.3. GLOBAL AUTO INJECTORS MARKET BY OTHERS 2012-2022 ($ MILLION) 17
CHAP 7. GLOBAL AUTO INJECTORS MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 18
7.1. GLOBAL AUTO INJECTORS MARKET BY REGION 2012-2022 ($ MILLION) 18
7.2. NORTH AMERICA 18
7.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 18
7.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.2.3.1. U.S. 18
7.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.2.3.2. CANADA 18
7.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.3. EUROPE 18
7.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 18
7.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.3.3.1. GERMANY 18
7.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.2. UK 19
7.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.3. FRANCE 19
7.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.4. SPAIN 19
7.3.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.5. REST OF EUROPE 19
7.3.3.5.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($ MILLION) 19
7.3.3.5.2. RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 19
7.3.3.5.3. OTHERS MARKET ESTIMATES AND FORECAST2012-2022($ MILLION) 19
7.3.3.5.4. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 19
7.4. ASIA PACIFIC 20
7.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 20
7.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.4.3.1. CHINA 20
7.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.4.3.2. INDIA 20
7.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.4.3.3. JAPAN 20
7.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.4.3.4. SOUTH KOREA 20
7.4.3.4.1. SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.3.4.2. SOUTH KOREA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.4.3.5. OTHERS 20
7.4.3.5.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($ MILLION) 21
7.4.3.5.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 21
7.5. MIDDLE EAST & AFRICA 21
7.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
7.6. LATIN AMERICA 21
7.6.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.6.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
7.6.2.1. BRAZIL 21
7.6.2.1.1. BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.6.2.1.2. BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
CHAP 8. COMPETITIVE LANDSCAPE 22
8.1. AMEDRA PHARMACEUTICALS LLC 23
8.1.1. COMPANY OVERVIEW 23
8.1.2. SCOT ANALYSIS 23
8.1.3. PRODUCT BENCHMARKING 23
8.1.4. STRATEGIC INITIATIVES 23
8.2. ANTARES PHARMA INC. 23
8.2.1. COMPANY OVERVIEW 23
8.2.2. SCOT ANALYSIS 23
8.2.3. PRODUCT BENCHMARKING 23
8.2.4. STRATEGIC INITIATIVES 23
8.3. BECTON, DICKINSON & COMPANY 23
8.3.1. COMPANY OVERVIEW 23
8.3.2. SCOT ANALYSIS 23
8.3.3. PRODUCT BENCHMARKING 23
8.3.4. STRATEGIC INITIATIVES 23
8.4. BIOGEN IDEC, INC. 23
8.4.1. COMPANY OVERVIEW 23
8.4.2. SCOT ANALYSIS 23
8.4.3. PRODUCT BENCHMARKING 23
8.4.4. STRATEGIC INITIATIVES 23
8.5. EPIPENS 23
8.5.1. COMPANY OVERVIEW 23
8.5.2. SCOT ANALYSIS 23
8.5.3. PRODUCT BENCHMARKING 23
8.5.4. STRATEGIC INITIATIVES 23
8.6. MYLAN INC. 23
8.6.1. COMPANY OVERVIEW 23
8.6.2. SCOT ANALYSIS 24
8.6.3. PRODUCT BENCHMARKING 24
8.6.4. STRATEGIC INITIATIVES 24
8.7. NOVARTIS INTERNATIONAL AG 24
8.7.1. COMPANY OVERVIEW 24
8.7.2. SCOT ANALYSIS 24
8.7.3. PRODUCT BENCHMARKING 24
8.7.4. STRATEGIC INITIATIVES 24
8.8. OWEN MUMFORD 24
8.8.1. COMPANY OVERVIEW 24
8.8.2. SCOT ANALYSIS 24
8.8.3. PRODUCT BENCHMARKING 24
8.8.4. STRATEGIC INITIATIVES 24
8.9. PA CONSULTING GROUP 24
8.9.1. COMPANY OVERVIEW 24
8.9.2. SCOT ANALYSIS 24
8.9.3. PRODUCT BENCHMARKING 24
8.9.4. STRATEGIC INITIATIVES 24
8.10. PFIZER INC. 24
8.10.1. COMPANY OVERVIEW 24
8.10.2. SCOT ANALYSIS 24
8.10.3. PRODUCT BENCHMARKING 24
8.10.4. STRATEGIC INITIATIVES 24
8.11. REBIJECT 24
8.11.1. COMPANY OVERVIEW 24
8.11.2. SCOT ANALYSIS 24
8.11.3. PRODUCT BENCHMARKING 24
8.11.4. STRATEGIC INITIATIVES 24
8.12. SANOFI 25
8.12.1. COMPANY OVERVIEW 25
8.12.2. SCOT ANALYSIS 25
8.12.3. PRODUCT BENCHMARKING 25
8.12.4. STRATEGIC INITIATIVES 25
8.13. SHL GROUP 25
8.13.1. COMPANY OVERVIEW 25
8.13.2. SCOT ANALYSIS 25
8.13.3. PRODUCT BENCHMARKING 25
8.13.4. STRATEGIC INITIATIVES 25
8.14. UNILIFE CORPORATION 25
8.14.1. COMPANY OVERVIEW 25
8.14.2. SCOT ANALYSIS 25
8.14.3. PRODUCT BENCHMARKING 25
8.14.4. STRATEGIC INITIATIVES 25
8.15. YPSOMED HOLDING AG 25
8.15.1. COMPANY OVERVIEW 25
8.15.2. SCOT ANALYSIS 25
8.15.3. PRODUCT BENCHMARKING 25
8.15.4. STRATEGIC INITIATIVES 25
TABLE 1 GLOBAL AUTO INJECTORS MARKET BY THERAPEUTIC APPLICATIONS 2012-2022 ($ MILLION) 25
TABLE 2 GLOBAL AUTO INJECTORS MARKET BY RHEUMATOID ARTHRITIS 2012-2022 ($ MILLION) 25
TABLE 3 GLOBAL AUTO INJECTORS MARKET BY MULTIPLE SCLEROSIS 2012-2022 ($ MILLION) 25
TABLE 4 GLOBAL AUTO INJECTORS MARKET BY ANAPHYLAXIS 2012-2022 ($ MILLION) 25
TABLE 5 GLOBAL AUTO INJECTORS MARKET BY OTHERS 2012-2022 ($ MILLION) 26
TABLE 6 GLOBAL AUTO INJECTORS MARKET BY TYPES 2012-2022 ($ MILLION) 26
TABLE 7 GLOBAL AUTO INJECTORS MARKET BY FILLABLE AUTO- INJECTORS 2012-2022 ($ MILLION) 26
TABLE 8 GLOBAL AUTO INJECTORS MARKET BY PREFILLED AUTO-INJECTORS 2012-2022 ($ MILLION) 26
TABLE 9 GLOBAL AUTO INJECTORS MARKET BY OTHERS 2012-2022 ($ MILLION) 26
TABLE 10 GLOBAL AUTO INJECTORS MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 26
TABLE 11 GLOBAL AUTO INJECTORS MARKET BY REGION 2012-2022 ($ MILLION) 26
TABLE 12 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 13 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 26
TABLE 14 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 15 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 16 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 17 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 18 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 19 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 20 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 26
TABLE 21 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 22 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 23 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 24 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 25 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 26 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 27 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 28 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 29 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 30 RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($ MILLION) 27
TABLE 31 RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 27
TABLE 32 OTHERS MARKET ESTIMATES AND FORECAST2012-2022($ MILLION) 27
TABLE 33 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 27
TABLE 34 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 35 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 27
TABLE 36 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 37 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 38 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 39 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 40 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 41 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 42 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 43 SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 44 SOUTH KOREA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 45 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($ MILLION) 28
TABLE 46 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 28
TABLE 47 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 48 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 49 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 50 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 51 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 52 BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
FIGURE 1 MARKET SHARE BY REGIONS 28
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 4 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 5 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 6 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 7 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 8 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 9 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 10 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 11 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 12 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 13 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 14 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 15 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 16 BRAZIL AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29